Cooperative interaction between Bcl-2 and Epstein-Barr virus latent membrane protein 1 in the growth transformation of human epithelial cells.
暂无分享,去创建一个
[1] J. Chen,et al. Induction of apoptosis in epithelial cells by Epstein-Barr virus latent membrane protein 1. , 1996, The Journal of general virology.
[2] E. Kieff. Epstein-Barr virus and its replication , 1996 .
[3] J. Taylor‐Papadimitriou,et al. bcl-2 overexpression inhibits cell death and promotes the morphogenesis, but not tumorigenesis of human mammary epithelial cells [published erratum appears in J Cell Biol 1995 Nov;131(4):following 1121] , 1995, The Journal of cell biology.
[4] M. Rowe,et al. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers , 1994, Journal of virology.
[5] T. McDonnell,et al. Bcl-2 oncogene blocks differentiation and extends viability but does not immortalize normal human keratinocytes. , 1994, International journal of oncology.
[6] E. Kieff,et al. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[7] S. Korsmeyer,et al. Latent membrane protein of Epstein-Barr virus induces cellular phenotypes independently of expression of Bcl-2 , 1993, Journal of virology.
[8] R. Poulsom,et al. BCL‐2 expression in adult and embryonic non‐haematopoietic tissues , 1993, The Journal of pathology.
[9] E. Kieff,et al. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation , 1993, Journal of virology.
[10] G. Evan,et al. The role of c-myc in cell growth. , 1993, Current opinion in genetics & development.
[11] G. Elia,et al. Bcl‐2 proto‐oncogene expression in epstein‐barr‐virus‐associated nasopharyngeal carcinoma , 1993, International journal of cancer.
[12] G. Evan,et al. Cooperative interaction between c-myc and bcl-2 proto-oncogenes , 1992, Nature.
[13] D. Green,et al. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. , 1992, Science.
[14] Gerard I. Evan,et al. Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.
[15] J. Cleveland,et al. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. , 1991, Oncogene.
[16] John Calvin Reed,et al. Mitochondrial protein p26 BCL2 reduces growth factor requirements of NIH3T3 fibroblasts. , 1991, Experimental cell research.
[17] E. Kieff,et al. Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell death , 1991, Cell.
[18] E. Kieff,et al. Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation , 1991, Journal of virology.
[19] Gwyn T. Williams,et al. Activation of Epstein–Barr virus latent genes protects human B cells from death by apoptosis , 1991, Nature.
[20] T. Hunter. Cooperation between oncogenes , 1991, Cell.
[21] T. McDonnell,et al. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) , 1991, Nature.
[22] M. Groudine,et al. Control of c-myc regulation in normal and neoplastic cells. , 1991, Advances in cancer research.
[23] R. Eisenman,et al. New light on Myc and Myb. Part II. Myb. , 1990, Genes & development.
[24] R. Schreiber,et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.
[25] A. Strasser,et al. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 , 1990, Nature.
[26] C. Croce,et al. Complementation by BCL2 and C-HA-RAS oncogenes in malignant transformation of rat embryo fibroblasts , 1990, Molecular and cellular biology.
[27] A. Levine,et al. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6 , 1990, Cell.
[28] G. Klein,et al. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein Barr virus , 1990, Nature.
[29] P. Nowell,et al. BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[30] L. Young,et al. EpsteinBarr virus latent membrane protein inhibits human epithelial cell differentiation , 1990, Nature.
[31] M. Cleary,et al. Membrane topology of the Bcl-2 proto-oncogenic protein demonstrated in vitro. , 1990, The Journal of biological chemistry.
[32] D. Spandidos,et al. The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis (review). , 1990, Anticancer research.
[33] R. Eisenman,et al. New light on Myc and Myb. Part I. Myc. , 1990, Genes & development.
[34] E. Kieff,et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. , 1989, The New England journal of medicine.
[35] S. Korsmeyer,et al. Growth- and tumor-promoting effects of deregulated BCL2 in human B-lymphoblastoid cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[36] S. Korsmeyer,et al. bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.
[37] Y. Tsujimoto. Overexpression of the human BCL-2 gene product results in growth enhancement of Epstein-Barr virus-immortalized B cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[38] E. Kieff,et al. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity , 1988, Journal of virology.
[39] David L. Vaux,et al. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.
[40] Pierre Busson,et al. Expression of Epstein‐Barr virus‐encoded proteins in nasopharyngeal carcinoma , 1988, International journal of cancer.
[41] V. Baichwal,et al. Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. , 1988, Oncogene.
[42] T. Tursz,et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. , 1988, The Journal of general virology.
[43] G. Mann,et al. Immunofluorescent quantification of ribonucleotide reductase M1 subunit and correlation with DNA content by flow cytometry. , 1987, Cytometry.
[44] E. Kieff,et al. An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes , 1987, Molecular and cellular biology.
[45] P. Nowell,et al. Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. , 1987, Science.
[46] E. Kieff,et al. Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus , 1986, Journal of virology.
[47] E. Kieff,et al. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells , 1985, Cell.
[48] D. Staunton,et al. Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells , 1985, Journal of virology.
[49] V. Diehl,et al. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. , 1970, Journal of the National Cancer Institute.
[50] M. Epstein,et al. VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. , 1964, Lancet.